Immutep announces new data from EFTISARC-NEO, a Phase II investigator-initiated trial of eftilagimod alpha in combination with radiotherapy plus KEYTRUDA for patients with soft tissue sarcoma, STS, will be presented at the Connective Tissue Oncology Society, CTOS, 2024 Annual Meeting taking place 13-16 November 2024, in San Diego, California. EFTISARC-NEO is the first to evaluate efti in a neoadjuvant setting, which importantly provides access to tumour tissue before and after treatment to assess efti’s impact on the tumour microenvironment. Initial efficacy data from this novel triple combination reported in May 2024 showed very encouraging results in the first six patients with the majority having deep responses rarely seen in STS patients with standard therapeutic approaches.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMMP:
- Immutep’s Efti Shows Promise in Cancer Therapy
- Immutep announces efficacy, safety results from TACTI-003 Phase IIb trial
- Immutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer
- Immutep: Quarterly Rebalance of S&P/ASX Indices
- Immutep Reports Increased Loss Despite Higher Income